News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alnylam Pharmaceuticals (ALNY) To Present Data From Its RNAi Therapeutic Programs Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR) At XIVth International Symposium On Amyloidosis (ISA)


3/21/2014 6:31:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that its scientists and collaborators will present pre-clinical and clinical data with patisiran (ALN-TTR02) and ALN-TTRsc – RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR) – at the XIVth International Symposium on Amyloidosis (ISA) being held April 27 – May 1, 2014 in Indianapolis, Indiana. Amongst other new data, the company presentations include results from a 283-patient natural history study of ATTR patients with familial amyloidotic polyneuropathy (FAP) that document the rate of disease progression.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES